Publication date: Jul 26, 2019
This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine, explained Giorgio V. Scagliotti, MD, PhD. -In the digital era, the ‘5 P’s’ of healthcare will predominate-preventive, predictive, participatory, personalized, [and] pertinent,” said Scagliotti, adding that a more personalized research strategy can lead to greater evolutions in research for biomedicine and prevention, as well as clinical medicine. In his presentation, -Changing Translational Research in NSCLC: Future Prospects,” during the 20th Annual International Lung Cancer Congress, Scagliotti, a professor of oncology of the University of Torino, Italy, discussed the promising, yet limited, evolution of therapeutic options, pointing to steps being taken to create a larger precision medicine ecosystem. -All of these kinds of things are exciting, but we need to think ahead, and we think to look for a new sort of precision medicine ecosystem,” he explained.
This includes digital health and mobile technologies, an increased focus on patient-reported outcomes (PROs), the emergence of curated real-world data sources, the use of predictive analytics and artificial intelligence (AI), shifts in the classes of agents being evaluated, availability of biomarker assays, changes in the regulatory landscape, and the availability of pools of pre-screened patients or direct-to-patient recruitment. Mobile technologies will also impact clinical trial designs, as they have already transformed clinical development, Scagliotti explained, citing telemedicine and virtual physician visits, connected biometric sensors, consumer mobile apps, disease management apps, consumer wearables, in-home connected virtual assessments, and web-based interactive programs. These tools have led to increased data sources-continuous data, contextual metadata, real-time data, and electronic PRO data-before evolving to facets like novel endpoints, digital biomarkers, companion apps, virtual trials and patient-centric designs, patient safety and centralized monitoring, virtual electronic consent, direct-to-patient recruitment, and work burden. One forward-thinking strategy is the TranslatiOnal Platform for de-orphaning malignant pleural MESOthelioma (TOPMESO), a biobank and patient samples that, through analyses, could lead to more effective therapeutic strategies for clinical studies and also determine minimally invasive biomarkers. The biobank and patient samples would comprise established primary lines, short-term cultures, malignant pleural mesothelioma tissue, immuno-organoids, and patient-derived xenografts.
|disease||DOID||malignant pleural MESOthelioma|
- Building the case for actionable ethics in digital health research supported by artificial intelligence.
- Emma Huang, J&J Innovation – 2019 Stanford Medicine Big Data | Precision Health
- Exploring the genetic landscape of solid tumors using whole-genome copy number analysis
- Population-scale DNA test could make personalized medicine effective and affordable for all
- AI in the Clinic Panel – 2019 Stanford Medicine Big Data | Precision Health
- Cigna Ventures leads $23M funding round in precision medicine company GNS Healthcare
- With Biomarker Expansion, Combinations and Personalized Medicine Continue to Rise
- Don Rucker, HHS – 2019 Stanford Medicine Big Data | Precision Health
- Big Data vs. Big Disease: How Algorithms Can Stop Pandemics | Wendy Taylor
- Precision Medicine & Health in Action: Practicing an N-of-1 Approach in the Clinic
- NGS Target Enrichment Solutions to Drive Discovery in Precision Medicine Research
- A decade of digital medicine innovation
- i2b2 tranSMART Foundation Harvard Symposium 2019 – Personalized Medicine
- Precision Medicine Has Dramatically Increased Survival Rates for One Patient in Ten. Scientists Are Looking to AI to Help with the Rest